Inhibition of [18F]FP-TZTP binding by loading doses of muscarinic agonists P-TZTP or FP-TZTP in vivo is not due to agonist-induced reduction in cerebral blood flow

Synapse

Volumn 50, Issue 2, 2003, Pages 151-163

  Shimoji, Kazuaki ^a   Esaki, Takanori ^b   Itoh, Yoshiaki ^b   Ravasi, Laura ^a,c   Cook, Michelle ^b   Jehle, Jane ^b   Jagoda, Elaine M ^a   Kiesewetter, Dale O ^a   Schmidt, Kathleen ^b   Sokoloff, Louis ^b   Eckelman, William C ^a,d  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^c UNIVERSITY OF MILAN   (Italy)

^d Building 10   (United States)

Author keywords

14C iodoantipyrine method; 18F FP TZTP; Inhibition study; M2 muscarinic receptors

Indexed keywords

[3 [3 (3 FLUOROPROPYL)THIO] 1,2,5 THIADIAZOL 4 YL] 1,2,5,6 TETRAHYDRO 1 METHYLPYRIDINE F 18; MUSCARINIC AGENT; MUSCARINIC M2 RECEPTOR AGONIST; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 3 (3 (PROPYLTHIO) 1,2,5 THIADIAZOL 4 YL) 1,2,5,6 TETRAHYDRO 1 METHYLPYRIDINE; 3-(3-(PROPYLTHIO)-1,2,5-THIADIAZOL-4-YL)-1,2,5,6-TETRAHYDRO-1-METHYLPYRIDINE; ATROPINE DERIVATIVE; CARBON; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FP TZTP; FP-TZTP; IODOPHENAZONE; METHYLATROPINE; MUSCARINIC M2 RECEPTOR; PHENAZONE; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ARTICLE; BINDING SITE; BRAIN BLOOD FLOW; CONTROLLED STUDY; ISOTOPE LABELING; LASER DOPPLER FLOWMETRY; MALE; NEUROLOGIC DISEASE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; ANIMAL; BINDING COMPETITION; BLOOD PRESSURE; BRAIN; BRAIN CIRCULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ADMINISTRATION ROUTE; DRUG EFFECT; DRUG INTERACTION; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; SCINTISCANNING; SPRAGUE DAWLEY RAT;

ANIMALS; ANTIPYRINE; ATROPINE DERIVATIVES; BINDING, COMPETITIVE; BLOOD PRESSURE; BRAIN; CARBON RADIOISOTOPES; CEREBROVASCULAR CIRCULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FLUORINE RADIOISOTOPES; LASER-DOPPLER FLOWMETRY; MALE; MUSCARINIC AGONISTS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, MUSCARINIC M2; THIAZOLES;

EID: 0141852962     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/syn.10257     Document Type: Article

References (39)

1. Adachi K, Takahashi S, Melzer P, Campos KL, Nelson T, Kennedy C, Sokoloff L. 1994. Increase in local cerebral blood flow associated with somatosensory activation are not mediated by NO. Am J Physiol 267:H2155-2162.
2. Aubert I, Araujo DM, Cécyre D, Robitaille Y, Gauthier S, Quirion R. 1992. Comparative alterations of nicotinic and muscarinic binding sites in Alzheimer's and Parkinson's disease. J Neurochem 58:529-541.
3. Barbelivien A, MacKenzie ET, Dauphin F. 1995. Regional cerebral blood flow responses to neurochemical stimulation of the substantia innominata in the anaesthetized rat. Neurosci Lett 190:81-84.
4. Bartus RT, Dean 3rd RL, Beer B, Lippa AS. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-417.
5. Biesold D, Inanami O, Sato A, Sato Y. 1989. Stimulation of nucleus basalis of Meynert increases cerebral cortical blood flow in rats. Neurosci Lett 98:39-44.
6. 18F]FP-TZTP: control and competition studies. J Cereb Blood Flow Metab 18:1130-1142.
7. Cortes R, Probst A, Tobler HJ, Palacios JM. 1986. Muscarinic cholinergic receptor subtypes in the human brain. II. Quantitative autoradiographic studies. Brain Res 362:239-253.
8. Cortes R, Probst A, Palacios JM. 1987. Quantitative light microscopic autoradiographic localization of cholinergic muscarinic receptors in the human brain: forebrain. Neuroscience 20:65-107.
9. Coyle JT, Price DL, Delong MR. 1983. Alzheimer's disease; a disorder of cortical cholinergic innervation. Science 219:1184-1190.
10. De Lay G, Weyne J, Demeester G, Leusen I. 1984. Response of local cerebral blood flow in the caudate nucleus of the cat to intraventricular administration of carbachol. Stroke 15:481-486.
11. Flynn DD, Mash DC. 1993. Distinct kinetic binding properties of N-[3H]-methylscopolamine afford differential labeling and localization of M1, M2, and M3 muscarinic receptor subtypes in primate brain. Synapse 14:283-296.
12. Frerichs KU, Feuerstein GZ. 1990. Laser-Doppler flowmetry-A review of its application for measuring cerebral and spinal cord blood flow. Mol Chem Neuropathol 12:55-70.
13. Freygang WH, Sokoloff L. 1958. Quantitative measurement of regional circulation in the central nervous system by the use of a radioactive gas. Adv Biol Med Phys 6:263-279.
14. Harukuni I, Takahashi H, Traystman RJ, Bhardwaj A, Kirsch JR. 2000. Oxotremorine induced cerebral hyperemia does not predict infarction volume in spontaneously hypertensive or stroke-prone rats. Crit Care Med 28:190-195.
15. Heistad DD, Marcus ML, Said SI, Gross PM. 1980. Effect of acetylcholine and vasoactive intestinal peptide on cerebral blood flow. Am J Physiol 239:H73-80.
16. Hernández MJ, Brennan RW, Bowman GS. 1978. Cerebral blood flow autoregulation in the rat. Stroke 9:150-154.
17. Jagoda EM, Kiesewetter DO, Shimoji K, Yamada M, Gomeza J, Wess J, Eckelman WC. 2003. Regional brain uptake of the muscarinic ligand [18F]FP-TZTP, is greatly decreased in M2 receptor knockout mice but not in M1, M3 and M4 receptor knockout mice. Neuropharmacology 44:653-661.
18. Jones SC, Radinsky CR, Furlan AJ, Chyatte D, Qu Y, Easley KA, Perez-Trepichio AD. 2002. Variability in the magnitude of the cerebral blood flow response and the shape of the cerebral blood flow-pressure autoregulation curve during hypotension in normal rats [corrected]. Anesthesiology 97:488-496.
19. 18F-labeled muscarinic agonist with M2 selectivity. J Med Chem 38:5-8.
20. Kiesewetter DO, Carson RE, Jagoda EM, Herscovitch P, Eckelman WC. 1999. In vivo muscarinic binding of 3-(alkylthio)-3-thiadiazoyl tetrahydropyridines. Synapse 31:29-40.
21. Kiesewetter DO, Vuong BK, Channing MA. 2003. The automated radiosynthesis of [18F]FP-TZTP Nucl Med Biol;30:73-77.
22. 3H]dihydrotetrabenazine to the vesicular monoamine transporter of rat brain: bolus vs. equilibrium studies. Eur J Pharmacol 331:161-168.
23. Kurosawa M, Sato A, Sato Y. 1989. Stimulation of the nucleus basalis of Meynert increases acetylcholine release in the cerebral cortex in rats. Neurosci Lett 98:45-50.
24. Levey AI. 1993. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissue and brain. Life Sci 52:441-448.
25. Li M, Yasuda RP, Wall SJ, Wellstein A, Wolfe BB. 1991. Distribution of m2 muscarinic receptors in rat brain using antisera selective for m2 receptors. Mol Pharmacol 40:28-35.
26. Mash DC, Flynn DD, Potter LT. 1985. Loss of M2 muscarinic receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228:1115-1117.
27. 1 blockade normalizes cerebrovascular autoregulation and reduces cerebral ischemia in spontaneously hypertensive rats. Stroke 31:2478-2486.
28. Nordberg A. 1999. PET studies and cholinergic therapy in Alzheimer's disease. Rev Neurol (Paris) 155:53-63.
29. Nordberg A, Svensson AL. 1998. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 19:465-480.
30. Patlak CS, Pettigrew KD. 1976. A method to obtain infusion schedules for prescribed blood concentration time courses. J Appl Physiol 40:458-462.
31. Podruchny TA, Connolly C, Bokde A, Herscovitch P, Eckelman WC, Kiesewetter DO, Sunderland T, Carson RE, Cohen RM. 2003. In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. Synapse 48:39-44.
32. Quirion R, Aubert I, Lapchak PA, Schaum RP, Teolis S, Gauthier S, Araujo M. 1989. Muscarinic receptor subtype in human neurodegenerative disorders: focus on Alzheimer's disease. Trends Pharmacol Sci Suppl 80-84.
33. 14C]antipyrine. Am J Physiol 234:H59-H66.
34. 1 selective muscarinic agonists. Synthesis structure-activity relationships of 3-(1,2,5-thiadiazoyl)-1,2,5,6-tetrahydro-1-methylpyridines. J Med Chem 35:2274-2283.
35. Sokoloff L. 1959. The action of drugs on the cerebral circulation. Pharmacol Rev 11:1-85.
36. Teitgen CS, Kirsch JR, Clavier N, Traystman RJ. 1995. Time-dependent inhibition of oxotremorine-induced cerebral hyperemia by N-nitro-L-arginine in cats. Stroke 26:2160-2165.
37. Woolf NJ, Butcher LL. 1985. Cholinergic system in the rat brain. II. Projection to the interpeduncular nucleus. Brain Res Bull 14:63-83.
38. Woolf NJ, Butcher LL. 1986. Cholinergic system in the rat brain. III. Projections from the pontomesencephalic tegmentum to the thalamus, tectum, basal ganglia, and basal forebrain. Brain Res Bull 16:603-637.
39. Woolf NJ, Eckenstein F, Butcher LL. 1984. Cholinergic system in the rat brain. I. Projection to the limbic telencephalon. Brain Res Bull 13:751-784.